The CANTOS trial randomized post-myocardial-infarction patients with persistently elevated high-sensitivity CRP to canakinumab or placebo. What distinguishes this trial conceptually from all prior lipid-lowering trials?

• A It proved that lowering LDL cholesterol independently reduces inflammation
• B It reduced recurrent cardiovascular events by targeting IL-1beta-mediated inflammation without any change in LDL cholesterol ✓
• C It showed that hsCRP itself must be lowered to achieve event reduction
• D It demonstrated equal benefit from canakinumab regardless of baseline hsCRP

Explanation

CANTOS provided direct evidence for the inflammatory hypothesis of atherothrombosis: canakinumab, a monoclonal antibody against IL-1beta, reduced recurrent cardiovascular events in post-MI patients with hsCRP above 2 mg/L while leaving LDL cholesterol completely unchanged. Canakinumab does not lower CRP as its mechanism of benefit; hsCRP served purely as a marker identifying systemic inflammation. A signal toward increased fatal infection was observed, tempering enthusiasm.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.